Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Business Segments

Income StatementBalance SheetCash FlowRatiosSegments
QuarterlyAnnualTTM
YoYQoQ
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Revenue by Product
Daybue$101.14M+19.6%$109.63M+13.3%$101.1M+10.8%$96.09M+13.6%$84.6M+11.4%
Nuplazid$166.92M+4.5%$174.36M+7.1%$177.53M+11.5%$168.48M+7.0%$159.72M+22.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does Acadia Pharmaceuticals break its business down?
Acadia Pharmaceuticals (ACAD) reports revenue by product across 2 parts — Daybue and Nuplazid. Each is extracted from the segment footnotes and tracked over time.
Where does Acadia Pharmaceuticals's segment data come from?
Segment breakdowns are pulled from the segment footnotes in Acadia Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.